Loading...
XNAS
GEHC
Market cap32bUSD
Jun 04, Last price  
71.13USD
1D
-0.04%
1Q
-16.72%
IPO
25.36%
Name

GE Healthcare Technologies Inc

Chart & Performance

D1W1MN
No data to show
P/E
16.34
P/S
1.66
EPS
4.35
Div Yield, %
0.17%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
3.41%
Revenues
19.67b
+0.61%
16,633,000,00017,164,000,00017,585,000,00018,341,000,00019,552,000,00019,672,000,000
Net income
1.99b
+27.10%
1,524,000,0002,058,000,0002,247,000,0001,916,000,0001,568,000,0001,993,000,000
CFO
1.95b
-7.14%
1,989,000,0001,687,000,0001,607,000,0002,113,000,0002,101,000,0001,951,000,000
Dividend
Oct 18, 20240.03 USD/sh

Profile

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
IPO date
Dec 15, 2022
Employees
50,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
19,672,000
0.61%
19,552,000
6.60%
18,341,000
4.30%
Cost of revenue
12,778,000
12,835,000
12,188,000
Unusual Expense (Income)
NOPBT
6,894,000
6,717,000
6,153,000
NOPBT Margin
35.04%
34.35%
33.55%
Operating Taxes
531,000
743,000
563,000
Tax Rate
7.70%
11.06%
9.15%
NOPAT
6,363,000
5,974,000
5,590,000
Net income
1,993,000
27.10%
1,568,000
-18.16%
1,916,000
-14.73%
Dividends
(55,000)
(41,000)
Dividend yield
0.15%
0.12%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,617,000
1,116,000
15,000
Long-term debt
735,000
9,168,000
8,620,000
Deferred revenue
705,000
630,000
Other long-term liabilities
14,518,000
6,643,000
1,752,000
Net debt
(910,000)
7,433,000
6,868,000
Cash flow
Cash from operating activities
1,951,000
2,101,000
2,113,000
CAPEX
(401,000)
(387,000)
(310,000)
Cash from investing activities
(914,000)
(558,000)
(398,000)
Cash from financing activities
(573,000)
(478,000)
(822,000)
FCF
6,313,000
5,788,000
5,239,000
Balance
Cash
2,889,000
2,494,000
1,445,000
Long term investments
373,000
357,000
322,000
Excess cash
2,278,400
1,873,400
849,950
Stockholders' equity
2,076,000
817,000
9,362,000
Invested Capital
23,021,000
23,704,000
19,143,050
ROIC
27.24%
27.89%
29.12%
ROCE
27.41%
27.32%
30.22%
EV
Common stock shares outstanding
459,000
458,000
453,926
Price
78.18
1.11%
77.32
32.44%
58.38
 
Market cap
35,884,620
1.33%
35,412,560
33.63%
26,500,208
 
EV
35,162,620
43,022,560
33,373,208
EBITDA
7,474,000
7,327,000
6,786,000
EV/EBITDA
4.70
5.87
4.92
Interest
505,000
542,000
77,000
Interest/NOPBT
7.33%
8.07%
1.25%